Feasibility of rituximab plus dose adjusted EPOCH supported pegfilgrastim for large B-cell lymphoma

Shuhei Kida

Presentation information

Oral Session

Oral Session 2-7B Aggressive Lymphoma: Clinical (2)

Sat. Oct 12, 2019 10:10 AM - 11:10 AM No.7 (Tokyo International Forum, 5F Hall D5)

Chair: Kazuyuki Shimada (Department of Hematology, Nagoya University Hospital)

[OS2-7B-6] Feasibility of rituximab plus dose adjusted EPOCH supported pegfilgrastim for large B-cell lymphoma

Shuhei Kida, Ryo Nakata, Kumi Shibata, Makiko Suga, Kazuhito Tsutsumi, Yuma Tada, Hiroaki Masaie, Shigeo Fuji, Hitoshi Yoshida, Jun Ishikawa (Hematol., Osaka International Cancer Institute, Osaka, Japan)

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.Password is written on a program book.